HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health And Wellness Recalls: More RIJ Pharmaceutical Private Label OTCs

Executive Summary

Geritrex recalls nearly 40,000 bottles of cough/cold and stool softener products mae by RIJ. Latest update to FDA's recalls database also includes cannabidiol-containing OTC lidocaine topicals marketed by Pharma-Natural Inc. and Herbal Doctor Remedies products the agency warned about in 2017.

You may also be interested in...



Herbal Doctor Remedies Continues Sales Despite Agreement To Halt Production

Business continues selling unapproved and misbranded drugs due to claims for products intended to be used as Chinese herbal medicines including treatment of autism, Alzheimer’s disease, herpes and cancer, says FDA says warning.

OTC Private Labeler RIJ Pharmaceutical Must 'Fully Remediate' Water System

FDA asks RIJ Pharmaceutical, which recalled a dozen products last year, to provide plans for developing a solid water system design and mixing process. It warns private label manufacturer about contaminated, "‘super-potency" OTC drugs that resulted from GMP violations.

OTC Private Labelers Recall CVS, Walmart Brand Products

Recalls include one lot of CVS Health Sinus Relief manufactured by Product Quest Manufacturing, Walmart's Equate laxative made by Lupin's US office and 12 cough and cold products marketed under Preferred Plus Pharmacy and other private label brands and made by RIJ Pharmaceutical Corp. Chart provides update on recent US OTC recalls.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel